Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 149 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (normal saline) Continuous Infusion Clear all
Not listed Phase 2 Interventional

Study to Determine if Pre- and Post- Operative TAP Catheters With Ropivacaine Versus Placebo Affects Anesthetic, Narcotic Dosing, and Pain Scores

NCT03149783
View directory record Official record
Conditions
Pain, Postoperative, Delirium, Anesthesia, Local
Interventions
Ropivacaine HCL, sodium chloride
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 25, 2026, 12:50 AM EDT
Terminated Phase 4 Interventional Results available

RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain

NCT03305055
View directory record Official record
Conditions
Acute Pain, Wound Care, Posttraumatic Stress Disorder
Interventions
ketamine, Fentanyl
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Sep 25, 2026, 12:50 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Perioperative Lidocaine and Ketamine in Abdominal Surgery

NCT04084548
View directory record Official record
Conditions
Postoperative Pain
Interventions
Lidocaine and ketamine, Lidocaine, Ketamine, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 25, 2026, 12:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

NCT00897676
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), placebo
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 25, 2026, 12:50 AM EDT
Withdrawn Phase 4 Interventional

Sphenopalatine Ganglion Nerve Block for Postdural Puncture Headache in Obstetrics

NCT03181464
View directory record Official record
Conditions
Postdural Puncture Headache, Cerebrospinal Fluid Leak, Spinal; Puncture, Complications, Headache
Interventions
Lidocaine 4%, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 25, 2026, 12:50 AM EDT
Terminated Phase 3 Interventional Results available

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

NCT04607668
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
Interventions
Trilaciclib, Placebo
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 25, 2026, 12:50 AM EDT
Terminated Phase 3 Interventional Results available

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

NCT02626455
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 25, 2026, 12:50 AM EDT
Terminated Phase 4 Interventional

Prevention of Phantom Limb and Stump Pain Using Ambulatory Continuous Peripheral Nerve Blocks: A Pilot Study

NCT00771862
View directory record Official record
Conditions
Amputation, Phantom Limb Pain, Stump Pain
Interventions
perineural ropivicaine
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 25, 2026, 12:50 AM EDT
Withdrawn Phase 4 Interventional

Bupivacaine Pain Pumps to Decrease Mastectomy Post-Operative Pain

NCT01494259
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine, Saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 25, 2026, 12:50 AM EDT
Withdrawn Not applicable Interventional

Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

NCT01613820
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Scopolamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 25, 2026, 12:50 AM EDT
Withdrawn Not applicable Interventional

Treatment of Postoperative Pain After Total Knee Arthroplasy Using Intravenous Lidocaine Infusion

NCT00616850
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Continuous femoral catheter block, Lidocaine, Preservative free normal saline
Procedure · Drug · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 25, 2026, 12:50 AM EDT
Terminated Phase 4 Interventional Results available

Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia

NCT04140396
View directory record Official record
Conditions
Rib Fractures
Interventions
Saline infusion, Lidocaine infusion
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 25, 2026, 12:50 AM EDT
Completed Phase 2 Interventional

Ketamine for the Treatment of Depression in Parkinson's Disease

NCT04944017
View directory record Official record
Conditions
Parkinson's Disease, Depression
Interventions
Ketamine Infusion, Placebo - Saline Infusion
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 25, 2026, 12:50 AM EDT
Completed Phase 2 Interventional

Tocilizumab in Cardiac Transplantation

NCT03644667
View directory record Official record
Conditions
Heart Transplant
Interventions
tocilizumab, Placebo, Standard of Care Triple IS
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Beverly Hills, California • La Jolla, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 25, 2026, 12:50 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.

NCT07079761
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm
Behavioral · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 25, 2026, 12:50 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Continuous Infusion Ropivacaine Interscalene Blocks

NCT02462382
View directory record Official record
Conditions
Full-thickness Rotator Cuff Tear
Interventions
Arthroscopic Rotator Cuff Repair, Ropivacaine, Saline
Procedure · Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 25, 2026, 12:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Novel Experimental COVID-19 Therapies Affecting Host Response

NCT04924660
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions
TXA127, TRV027, Placebo, Fostamatinib
Drug
Lead sponsor
Sean Collins
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 25, 2026, 12:50 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy

NCT00765128
View directory record Official record
Conditions
Renal Calculus, Kidney Stones
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Sep 25, 2026, 12:50 AM EDT
Completed Not applicable Interventional

Laparoscopic Ventral Hernia Repair With Elastomeric Pain Pump

NCT00472134
View directory record Official record
Conditions
Hernia, Ventral
Interventions
bupivacaine, On-Q PainBuster pump
Drug · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 25, 2026, 12:50 AM EDT
Recruiting Phase 4 Interventional

Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

NCT04166877
View directory record Official record
Conditions
Trauma, Acute Pain
Interventions
Magnesium Sulfate in Parenteral Dosage Form, Normal saline placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 25, 2026, 12:50 AM EDT
Withdrawn Not applicable Interventional

Intravenous Lidocaine and Quality of Recovery After Cesarean Delivery

NCT02257346
View directory record Official record
Conditions
Pregnancy
Interventions
Lidocaine, Normal Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 25, 2026, 12:50 AM EDT
Active, not recruiting Early Phase 1 Interventional

Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)

NCT04846829
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, intermittent theta burst stimulation, intravenous citalopram hydrochloride (CIT), continuous theta burst stimulation
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 25, 2026, 12:50 AM EDT
Completed Phase 4 Interventional Results available

Single-shot TAP Block vs Continuous TAP Block

NCT02475031
View directory record Official record
Conditions
Postoperative Pain
Interventions
TAP-C, TAP-S
Device · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Sep 25, 2026, 12:50 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 25, 2026, 12:50 AM EDT